Eventide Asset Management LLC Makes New Investment in uniQure N.V. $QURE

Eventide Asset Management LLC bought a new position in shares of uniQure N.V. (NASDAQ:QURE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 498,212 shares of the biotechnology company’s stock, valued at approximately $11,922,000.

A number of other institutional investors also recently bought and sold shares of QURE. Torren Management LLC purchased a new stake in uniQure during the fourth quarter worth $28,000. Jones Financial Companies Lllp boosted its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc purchased a new stake in uniQure during the fourth quarter worth $48,000. Smartleaf Asset Management LLC purchased a new stake in uniQure during the fourth quarter worth $48,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in uniQure during the third quarter worth $50,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Insiders Place Their Bets

In other news, Director Leonard E. Post sold 1,993 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the sale, the director directly owned 35,494 shares in the company, valued at $960,467.64. This represents a 5.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Madhavan Balachandran sold 1,993 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director owned 43,254 shares in the company, valued at $1,170,453.24. This trade represents a 4.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 85,817 shares of company stock valued at $2,232,383. Insiders own 4.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Barclays decreased their target price on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Monday, March 23rd. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, April 20th. Finally, Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus target price of $42.83.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $27.57 on Monday. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The stock’s fifty day simple moving average is $22.52 and its 200-day simple moving average is $21.76. The company has a market capitalization of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. As a group, equities research analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.